Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab plus R-CHOP versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma
2021-000168-31Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Sep 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-free survival. Started Sep 2022; status: active.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2021-000168-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000168-31.